GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLAUKOS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$166.96+2.12 (+1.29%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
GLAUKOS Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | $513.84M | $462.19M | $421.07M | $386.06M | $351.85M | $324.19M | $303.28M | $279.70M | $262.01M | $248.03M | $237.04M | $229.35M | 83.8% | +46.0% |
| Corneal Health | $99.00M | $89.16M | $86.37M | $83.76M | $81.11M | $80.33M | $80.21M | $80.64M | $79.71M | $78.40M | $77.67M | $74.23M | 16.2% | +22.1% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $468.54M | $412.32M | $375.04M | $342.61M | $311.18M | $287.48M | $270.09M | $252.93M | $238.31M | $227.40M | $219.40M | $212.28M | 76.5% | +50.6% |
| International | $144.30M | $139.03M | $132.40M | $127.21M | $121.78M | $117.05M | $113.39M | $107.42M | $103.42M | $99.04M | $95.32M | $91.30M | 23.5% | +18.5% |
From the segment and revenue-disaggregation notes of Glaukos's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.